Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Pancreatic Cancer. 10 results shown below.

Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

[Complete title: Phase I study of neo-adjuvant RO7009789 alone or neo-adjuvant RO7009789 plus nab-paclitaxel and gemcitabine followed by adjuvant RO7009789 plus nab-paclitaxel and gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 9627
Phase: I

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

[Complete title: Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers]
Principal Investigator: Gabriela Chiorean
Study Number: 9078
Phase: I

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

[Complete title: Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: S1513
Phase: II

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)

[Complete title: A Phase 1A/1B Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers]
Principal Investigator: John Thompson, MD
Study Number: 20151981
Phase: I

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

[Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements]
Principal Investigator: Gabriela Chiorean
Study Number: 20152369
Phase: II

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

[Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma]
Principal Investigator: Andrew Coveler, MD
Study Number: 20152434
Phase: III

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

[Complete title: Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies]
Principal Investigator: Ryan Cassaday
Study Number: 20152763
Phase: I

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

[Complete title: I3Y-MC-JPCJ(a) An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 20162123
Phase: II

A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer

[Complete title: A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 20170696
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials